|
1.
|
Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III. MedStar authors:
- Garcia-Garcia, Hector M
- Waksman, Ron
Year: 2018
Citation: - Catheterization & Cardiovascular Interventions. 92(7):E502-E511, 2018 Dec 01.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Abizaid A, Alves Lemos P, Barbato E, BIOSOLVE-II and III investigators, Christiansen EH, Garcia-Garcia HM, Haude M, Ince H, Kische S, Tolg R, Van Mieghem NM, Verheye S, von Birgelen C, Waksman R
|
|
2.
|
Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. MedStar authors:
- Garcia-Garcia, Hector M
- Waksman, Ron
Year: 2016
Citation: - European Heart Journal. 37(35):2701-9, 2016 Sep 14
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Abizaid A, Christiansen EH, Eeckhout E, Escaned J, Garcia-Garcia HM, Haude M, Ince H, Kaiser C, Lemos PA, Lim ST, Neumann FJ, Onuma Y, Toelg R, von Birgelen C, Waksman R, Wijns W
|